News

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted ...

Corbus Gets FDA Fast Track Designation for Cancer Drug

Corbus Pharmaceuticals received fast track designation from the FDA for CRB-701, a drug to be used in the treatment of head and neck squamous cell carcinoma, a kind of cancer. A continuing clinical ...